Women's Health Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Women's Health Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Breast Cancer
Earlier fulvestrant use in heavily pretreated older women may be more effective
March 10th, 2005
Study results suggest that use of fulvestrant earlier in the treatment strategy for heavily pretreated postmenopausal women with breast cancer may yield more effective response. "Fulvestrant (Faslodex) is a new estrogen receptor (ER) antagonist that has no agonist effects. It binds, blocks, and accelerates degradation of the ER, leading to a complete abrogation of estrogen-sensitive gene transcription. In postmenopausal women with advanced breast cancer progressing on prior endocrine therapy, fulvestrant is at least as effective as the third-generation aromatase inhibitor (AT) anastrozole," said S. Franco and colleagues, Breast Cancer Institute, Hollywood,...
Source: Women's Health Weekly (2005-03-10)
|
